Tag Archives: oral therapy growth

John Santilli quoted in Modern Medicine: FDA warns of rare brain infection with MS drug Tecfidera

New oral therapies Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries. “Although this is Tecfidera’s first incident tied to PML use in more than 100,000 […]